FHIR IG analytics| Package | de.medizininformatikinitiative.kerndatensatz.onkologie |
| Resource Type | ConceptMap |
| Id | ConceptMap-mii-cm-onko-atc-transitions-2024.json |
| FHIR Version | R4 |
| Source | https://medizininformatik-initiative.github.io/kerndatensatzmodul-onkologie/2027.0.0-ballot.1/ConceptMap-mii-cm-onko-atc-transitions-2024.html |
| URL | https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ConceptMap/mii-cm-onko-atc-transitions-2024 |
| Version | 2027.0.0-ballot.1 |
| Status | active |
| Date | 2024-12-12 |
| Name | MII_CM_Onko_ATC_Transitions_2024 |
| Title | MII CM Onko ATC Code Changes 2023 to 2024 |
| Realm | de |
| Description | Diese ConceptMap dokumentiert die ATC-Code-Änderungen von 2023 zu 2024. Mehrere immunmodulatorische Substanzen wurden in neue Kategorien umklassifiziert, und Kombinationspräparate erhielten neue Codes. |
| Purpose | Migration von ATC-Codes für immunmodulatorische Substanzen und Kombinationspräparate, die 2024 umkodiert wurden. |
No resources found
| CodeSystem | ||
| de.fhir.terminologie-basis#1.0.0-alpha1 | atc | ATC |
| ValueSet | ||
| de.medizininformatikinitiative.kerndatensatz.onkologie#2027.0.0-ballot.1 | mii-vs-onko-systemische-therapie-substanzen-2023 | MII VS Onkologie Systemische Therapie Substanzen ATC 2023 |
| de.medizininformatikinitiative.kerndatensatz.onkologie#2027.0.0-ballot.1 | mii-vs-onko-systemische-therapie-substanzen-2024 | MII VS Onkologie Systemische Therapie Substanzen ATC 2024 |
Note: links and images are rebased to the (stated) source
English
Generated Narrative: ConceptMap mii-cm-onko-atc-transitions-2024
Mapping from MII VS Onkologie Systemische Therapie Substanzen ATC 2023 to MII VS Onkologie Systemische Therapie Substanzen ATC 2024
Mapping from http://fhir.de/CodeSystem/bfarm/atc (Atc) to http://fhir.de/CodeSystem/bfarm/atc (Atc)
| Source Code | Relationship | Target Code | Comment |
| L04AA34 (Alemtuzumab) | is equivalent to | L04AG06 (Alemtuzumab) | Reklassifizierung innerhalb der Immunsuppressiva |
| L04AA26 (Belimumab) | is equivalent to | L04AG04 (Belimumab) | |
| L04AA25 (Eculizumab) | is equivalent to | L04AJ01 (Eculizumab) | Reklassifizierung zu Komplement-Inhibitoren |
| L04AA21 (Efalizumab) | is equivalent to | L04AG02 (Efalizumab) | |
| L01EG02 (Everolimus) | is equivalent to | L04AH02 (Everolimus) | Zusätzliche Klassifizierung als Immunsuppressivum (behält auch L01EG02) |
| L04AA27 (Fingolimod) | is equivalent to | L04AE01 (Fingolimod) | Reklassifizierung zu Sphingosin-1-Phosphat-Rezeptor-Modulatoren |
| L04AA13 (Leflunomid) | is equivalent to | L04AK01 (Leflunomid) | |
| L01FX24 (Mosunetuzumab) | is equivalent to | L01FX25 (Mosunetuzumab) | Code-Anpassung innerhalb der bispezifischen Antikörper |
| L04AA02 (Muromonab-CD3) | is equivalent to | L04AG01 (Muromonab-CD3) | |
| L04AA23 (Natalizumab) | is equivalent to | L04AG03 (Natalizumab) | |
| L01XY03 (Nivolumab und Relatlimab) | is equivalent to | L01FY02 (Nivolumab und Relatlimab) | Reklassifizierung zu Kombinationen monoklonaler Antikörper |
| L01FA02 (Ofatumumab) | is equivalent to | L04AG12 (Ofatumumab) | Zusätzliche Klassifizierung als Immunsuppressivum (behält auch L01FA02) |
| L01XY02 (Pertuzumab und Trastuzumab) | is equivalent to | L01FY01 (Pertuzumab und Trastuzumab) | Reklassifizierung zu Kombinationen monoklonaler Antikörper |
| L04AA10 (Sirolimus) | is equivalent to | L04AH01 (Sirolimus) | Reklassifizierung zu mTOR-Inhibitoren (Immunsuppressiva) |
German
Generated Narrative: ConceptMap mii-cm-onko-atc-transitions-2024
Mapping from MII VS Onkologie Systemische Therapie Substanzen ATC 2023 to MII VS Onkologie Systemische Therapie Substanzen ATC 2024
Mapping from http://fhir.de/CodeSystem/bfarm/atc (Atc) to http://fhir.de/CodeSystem/bfarm/atc (Atc)
| Source Code | Relationship | Target Code | Comment |
| L04AA34 (Alemtuzumab) | is equivalent to | L04AG06 (Alemtuzumab) | Reklassifizierung innerhalb der Immunsuppressiva |
| L04AA26 (Belimumab) | is equivalent to | L04AG04 (Belimumab) | |
| L04AA25 (Eculizumab) | is equivalent to | L04AJ01 (Eculizumab) | Reklassifizierung zu Komplement-Inhibitoren |
| L04AA21 (Efalizumab) | is equivalent to | L04AG02 (Efalizumab) | |
| L01EG02 (Everolimus) | is equivalent to | L04AH02 (Everolimus) | Zusätzliche Klassifizierung als Immunsuppressivum (behält auch L01EG02) |
| L04AA27 (Fingolimod) | is equivalent to | L04AE01 (Fingolimod) | Reklassifizierung zu Sphingosin-1-Phosphat-Rezeptor-Modulatoren |
| L04AA13 (Leflunomid) | is equivalent to | L04AK01 (Leflunomid) | |
| L01FX24 (Mosunetuzumab) | is equivalent to | L01FX25 (Mosunetuzumab) | Code-Anpassung innerhalb der bispezifischen Antikörper |
| L04AA02 (Muromonab-CD3) | is equivalent to | L04AG01 (Muromonab-CD3) | |
| L04AA23 (Natalizumab) | is equivalent to | L04AG03 (Natalizumab) | |
| L01XY03 (Nivolumab und Relatlimab) | is equivalent to | L01FY02 (Nivolumab und Relatlimab) | Reklassifizierung zu Kombinationen monoklonaler Antikörper |
| L01FA02 (Ofatumumab) | is equivalent to | L04AG12 (Ofatumumab) | Zusätzliche Klassifizierung als Immunsuppressivum (behält auch L01FA02) |
| L01XY02 (Pertuzumab und Trastuzumab) | is equivalent to | L01FY01 (Pertuzumab und Trastuzumab) | Reklassifizierung zu Kombinationen monoklonaler Antikörper |
| L04AA10 (Sirolimus) | is equivalent to | L04AH01 (Sirolimus) | Reklassifizierung zu mTOR-Inhibitoren (Immunsuppressiva) |
{
"resourceType": "ConceptMap",
"id": "mii-cm-onko-atc-transitions-2024",
"meta": {
"extension": [
{
"url": "http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-license",
"valueCode": "CC-BY-4.0"
},
{
"extension": [
{
"url": "packageId",
"valueId": "de.medizininformatikinitiative.kerndatensatz.onkologie"
},
{
"url": "version",
"valueString": "2027.0.0-ballot.1"
},
{
"url": "uri",
"valueUri": "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko"
}
],
"url": "http://hl7.org/fhir/StructureDefinition/package-source"
}
],
"profile": [
"http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-shareableconceptmap",
"http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-publishableconceptmap"
]
},
"text": {
"status": "generated",
"div": "<!-- snip (see above) -->"
},
"extension": [
{
"url": "http://hl7.org/fhir/StructureDefinition/cqf-knowledgeCapability",
"valueCode": "shareable"
},
{
"url": "http://hl7.org/fhir/StructureDefinition/cqf-knowledgeCapability",
"valueCode": "publishable"
},
{
"url": "http://hl7.org/fhir/StructureDefinition/artifact-versionPolicy",
"valueCodeableConcept": {
"coding": [
{
"system": "http://terminology.hl7.org/CodeSystem/artifact-version-policy-codes",
"code": "package",
"display": "Package"
}
]
}
},
{
"url": "http://hl7.org/fhir/StructureDefinition/resource-approvalDate",
"valueDate": "2026-09-15"
},
{
"url": "http://hl7.org/fhir/StructureDefinition/artifact-topic",
"valueCodeableConcept": {
"coding": [
{
"system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
"code": "C3262"
}
]
}
},
{
"url": "http://hl7.org/fhir/StructureDefinition/artifact-author",
"valueContactDetail": {
"telecom": [
{
"system": "email",
"value": "thomas.debertshaeuser@charite.de"
}
]
}
},
{
"url": "http://hl7.org/fhir/StructureDefinition/artifact-editor",
"valueContactDetail": {
"name": "Taskforce Core Data Set"
}
},
{
"url": "http://hl7.org/fhir/StructureDefinition/artifact-reviewer",
"valueContactDetail": {
"name": "Interoperability Working Group",
"telecom": [
{
"system": "url",
"value": "https://www.medizininformatik-initiative.de/en/collaboration/interoperability-working-group"
}
]
}
},
{
"url": "http://hl7.org/fhir/StructureDefinition/artifact-reviewer",
"valueContactDetail": {
"name": "National Steering Committee",
"telecom": [
{
"system": "url",
"value": "https://www.medizininformatik-initiative.de/en/collaboration/national-steering-committee"
}
]
}
},
{
"url": "http://hl7.org/fhir/StructureDefinition/artifact-endorser",
"valueContactDetail": {
"name": "Interoperability Working Group",
"telecom": [
{
"system": "url",
"value": "https://www.medizininformatik-initiative.de/en/collaboration/interoperability-working-group"
}
]
}
},
{
"url": "http://hl7.org/fhir/StructureDefinition/artifact-endorser",
"valueContactDetail": {
"name": "National Steering Committee",
"telecom": [
{
"system": "url",
"value": "https://www.medizininformatik-initiative.de/en/collaboration/national-steering-committee"
}
]
}
},
{
"url": "http://hl7.org/fhir/StructureDefinition/artifact-versionAlgorithm",
"valueCoding": {
"system": "http://hl7.org/fhir/version-algorithm",
"code": "semver",
"display": "SemVer"
}
},
{
"url": "http://hl7.org/fhir/StructureDefinition/resource-effectivePeriod",
"valuePeriod": {
"start": "2027"
}
}
],
"url": "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ConceptMap/mii-cm-onko-atc-transitions-2024",
"version": "2027.0.0-ballot.1",
"name": "MII_CM_Onko_ATC_Transitions_2024",
"title": "MII CM Onko ATC Code Changes 2023 to 2024",
"status": "active",
"experimental": false,
"date": "2024-12-12",
"publisher": "Medizininformatik Initiative",
"contact": [
{
"name": "Medizininformatik Initiative",
"telecom": [
{
"system": "url",
"value": "https://www.medizininformatik-initiative.de/"
}
]
}
],
"description": "Diese ConceptMap dokumentiert die ATC-Code-Änderungen von 2023 zu 2024. Mehrere immunmodulatorische Substanzen wurden in neue Kategorien umklassifiziert, und Kombinationspräparate erhielten neue Codes.",
"jurisdiction": [
{
"coding": [
{
"system": "urn:iso:std:iso:3166",
"code": "DE",
"display": "Germany"
}
]
}
],
"purpose": "Migration von ATC-Codes für immunmodulatorische Substanzen und Kombinationspräparate, die 2024 umkodiert wurden.",
"sourceCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ValueSet/mii-vs-onko-systemische-therapie-substanzen-2023",
"targetCanonical": "https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ValueSet/mii-vs-onko-systemische-therapie-substanzen-2024",
"group": [
{
"source": "http://fhir.de/CodeSystem/bfarm/atc",
"target": "http://fhir.de/CodeSystem/bfarm/atc",
"element": [
{
"code": "L04AA34",
"display": "Alemtuzumab",
"target": [
{
"code": "L04AG06",
"display": "Alemtuzumab",
"equivalence": "equivalent",
"comment": "Reklassifizierung innerhalb der Immunsuppressiva"
}
]
},
{
"code": "L04AA26",
"display": "Belimumab",
"target": [
{
"code": "L04AG04",
"display": "Belimumab",
"equivalence": "equivalent"
}
]
},
{
"code": "L04AA25",
"display": "Eculizumab",
"target": [
{
"code": "L04AJ01",
"display": "Eculizumab",
"equivalence": "equivalent",
"comment": "Reklassifizierung zu Komplement-Inhibitoren"
}
]
},
{
"code": "L04AA21",
"display": "Efalizumab",
"target": [
{
"code": "L04AG02",
"display": "Efalizumab",
"equivalence": "equivalent"
}
]
},
{
"code": "L01EG02",
"display": "Everolimus",
"target": [
{
"code": "L04AH02",
"display": "Everolimus",
"equivalence": "equivalent",
"comment": "Zusätzliche Klassifizierung als Immunsuppressivum (behält auch L01EG02)"
}
]
},
{
"code": "L04AA27",
"display": "Fingolimod",
"target": [
{
"code": "L04AE01",
"display": "Fingolimod",
"equivalence": "equivalent",
"comment": "Reklassifizierung zu Sphingosin-1-Phosphat-Rezeptor-Modulatoren"
}
]
},
{
"code": "L04AA13",
"display": "Leflunomid",
"target": [
{
"code": "L04AK01",
"display": "Leflunomid",
"equivalence": "equivalent"
}
]
},
{
"code": "L01FX24",
"display": "Mosunetuzumab",
"target": [
{
"code": "L01FX25",
"display": "Mosunetuzumab",
"equivalence": "equivalent",
"comment": "Code-Anpassung innerhalb der bispezifischen Antikörper"
}
]
},
{
"code": "L04AA02",
"display": "Muromonab-CD3",
"target": [
{
"code": "L04AG01",
"display": "Muromonab-CD3",
"equivalence": "equivalent"
}
]
},
{
"code": "L04AA23",
"display": "Natalizumab",
"target": [
{
"code": "L04AG03",
"display": "Natalizumab",
"equivalence": "equivalent"
}
]
},
{
"code": "L01XY03",
"display": "Nivolumab und Relatlimab",
"target": [
{
"code": "L01FY02",
"display": "Nivolumab und Relatlimab",
"equivalence": "equivalent",
"comment": "Reklassifizierung zu Kombinationen monoklonaler Antikörper"
}
]
},
{
"code": "L01FA02",
"display": "Ofatumumab",
"target": [
{
"code": "L04AG12",
"display": "Ofatumumab",
"equivalence": "equivalent",
"comment": "Zusätzliche Klassifizierung als Immunsuppressivum (behält auch L01FA02)"
}
]
},
{
"code": "L01XY02",
"display": "Pertuzumab und Trastuzumab",
"target": [
{
"code": "L01FY01",
"display": "Pertuzumab und Trastuzumab",
"equivalence": "equivalent",
"comment": "Reklassifizierung zu Kombinationen monoklonaler Antikörper"
}
]
},
{
"code": "L04AA10",
"display": "Sirolimus",
"target": [
{
"code": "L04AH01",
"display": "Sirolimus",
"equivalence": "equivalent",
"comment": "Reklassifizierung zu mTOR-Inhibitoren (Immunsuppressiva)"
}
]
}
]
}
]
}